Cytokinetics, Inc.
Cytokinetics Announces Q1 2025 Financial Results and Business Update
Summary
On May 6, 2025, Cytokinetics, Incorporated reported its Q1 2025 financial results, revealing a net loss of $161.4 million, or $(1.36) per share, compared to a net loss of $135.6 million, or $(1.33) per share, in Q1 2024. The company also provided updates on its clinical trials for aficamten, including the completion of enrollment in ACACIA-HCM ahead of schedule and expectations to share topline results in 1H 2026. The company maintained its full-year 2025 financial guidance and reported approximately $1.1 billion in cash, cash equivalents, and investments as of March 31, 2025.
Profitelligence Alerts
Get alerts for CYTK
Be first to know when Cytokinetics, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Cytokinetics, Inc.
Cytokinetics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel muscle activators as potential treatments for debilitating diseases. Primarily, the company's work aims to address unmet medical needs in the fields of neurology and cardiology, offering therapeutic solutions that target muscle function. Cytokinetics' research centers on small molecule drugs that modulate muscle performance, which could significantly aid patients suffering from heart failure, amyotrophic lateral sclerosis (ALS), and other muscle-related conditions. The company is actively involved in clinical trials and collaborates with other notable entities in its quest for innovative medical advancements. Its contributions to the healthcare sector exemplify the growing role of targeted therapy in improving patient outcomes. Headquartered in South San Francisco, California, Cytokinetics operates as a key player in the biotechnology landscape, with a commitment to pioneering treatments that leverage the complex mechanisms of muscle biology.
Official SEC Documents
Advertisement